arrow
J

Julie N. Graff

veterans health administration (vha)
H指数:30
被引数:5,056

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial

基于互联网的生活方式干预以消除前列腺癌幸存者肥胖脆弱性的随机对照试验(iLIVE)方案:一种I型混合效果实施试验

2026-03-250
OAAI
Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey

识别癌症退伍军人耳毒性管理中的差距与改进机会:基于回顾性队列研究和肿瘤科医生调查的证据

2026-02-150
OAAI
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types

肿瘤相关雄激素受体活性升高与免疫浸润不良及免疫治疗反应差相关,并跨越多种癌症类型

2026-01-012
PRE
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Niraparib和abiraterone acetate联合prednisone治疗HRR缺陷型转移性去势敏感前列腺癌:一项随机III期试验

2025-10-070
OAAI
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Pembrolizumab联合enzalutamide治疗转移性去势抵抗性前列腺癌在enzalutamide治疗进展: 2期主题199研究的队列4和5

2024-08-121
PRE
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
2023-11-114
OAAI
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
2021-12-0111
OAAI